Myricitrin

Myricitrin

SCHEMBL7926047

C[C@@H]1O[C@@H](Oc2c(-c3cc(O)c(O)c(O)c3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@H](O)[C@H]1O.O=c1c(O)c(-c2ccccc2)oc2ccccc12

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 5/20 0.79
POLB P06746 4/20 0.79
GAA P10253 4/20 0.79
L3MBTL1 Q9Y468 4/20 0.79
KDM4E B2RXH2 4/20 0.79
MAPT P10636 3/20 0.79
SLCO2B1 O94956 3/20 0.79
ALDH1A1 P00352 2/20 0.79
RECQL P46063 2/20 0.79
MPI P34949 1/20 0.79
NAMPT P43490 1/20 0.79
TDP1 Q9NUW8 1/20 0.79
NQO2 P16083 1/20 0.71
EPHX2 P34913 4/20 0.69
XDH P47989 4/20 0.69
MAOA P21397 3/20 0.69
AKR1B1 P15121 2/20 0.69
PIM2 Q9P1W9 2/20 0.69
CA12 O43570 1/20 0.69
CA2 P00918 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercitrin SCHEMBL7920286 0.94 P4HB (0.80) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL6361658 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL226023 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL12640019 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL244345 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL226022 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL13240936 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL22822137 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL22788153 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E
Myricitrin SCHEMBL30637444 0.89 P4HB (1.00) P4HBPOLBGAAL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1100539-A2 COMBINATION OF ACTIVE SUBSTANCES, ESPECIALLY FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC ORGANIC LESIONS AND REPERFUSION SYNDROMES Vascular Biotech GmbH (DE) 2001-05-23 EP disclosed
WO-2000007578-A2 COMBINATION OF ACTIVE SUBSTANCES, ESPECIALLY FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC ORGANIC LESIONS AND REPERFUSION SYNDROMES VASCULAR BIOTECH GMBH (DE) 2000-02-17 WO disclosed